The next CRCL/CLB seminar will take place Friday the 13th of January, at 11.30am in the JL Requin meeting room (Cheney D, lower floor) We are pleased to welcome Oskarsson Thordur (HI-STEM The Heidelberg Institute for Stem Cell Technology and Experimental Medicine).
The 3rd CRCL Symposium will welcome you on the 25th-27th September 2017 ! More information on our website here.
The 1st International Symposium "Immune Responses in Cancer and Infection" jointly organized by the CRCL and the CIRI (International Research Centre in Infectiology) will take place in Lyon, February 13-15 2017 ! Information, program and registration: click here
Follow the CRCL news on Twitter!
There are several positions available at the CRCL: click here
Stage M2 Recherche en Immuno-oncologie (profil recherché : Interne en Anatomopathologie) : click here (deadline January the 15th)
A postdoc position in the team of F. Zoulim : click here
- poste d'ingénieur d'étude ou AI en immunomarquage : cliquez ici
A 2 year post-doctoral position is available in the Team "Nuclear Domains and Pathologies" to work on an ANR funded project on Pancreatic Cancer Research. Click here
- A short-term (CDD) technical position is available at the Immunomonitoring platform: click here
Other positions 2016
- 1 postdoc position is available in the team of F. Zoulim, supervised by D. Durantel and J. Lucifora. Click here
- A Computational Biologist/Immunology position is available in the team of C. Caux and JY Blay. click here
- Other postdoc positions are available in the teams of M. Gabut and J. Marie: click here
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
29 November 2016
This work involved the team of Alain Puisieux.
Targeted therapies with MAPK inhibitors (MAPKi) are faced with severe problems of resistance in BRAF-mutant melanoma. In parallel to the acquisition of genetic mutations, melanoma cells may also adapt to the drugs through phenotype switching. The ZEB1 transcription factor, a known inducer of EMT and invasiveness, is now considered as a genuine oncogenic factor required for tumor initiation, cancer cell plasticity, and drug resistance in carcinomas. Here, we show that high levels of ZEB1 expression are associated with inherent resistance to MAPKi in BRAFV600-mutated cell lines and tumors.
PubMed access: click here
Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers
25 March 2016
This study involves the team of Patrick Mehlen.
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
PubMed access: click here